

Dated: March 30, 2023.
Thomas V. Curtin, Jr.,
*Executive Director, Joint Board for the
 Enrollment of Actuaries.*
 [FR Doc. 2023-06977 Filed 4-3-23; 8:45 am]
BILLING CODE 4830-01-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-1160]

**Importer of Controlled Substances
 Application: Sharp Clinical Services,
 LLC**

AGENCY: Drug Enforcement
 Administration, Justice.

ACTION: Notice of application.

SUMMARY: Sharp Clinical Services, LLC
 has applied to be registered as an
 importer of basic class(es) of controlled
 substance(s). Refer to **SUPPLEMENTARY
 INFORMATION** listed below for further
 drug information.

DATES: Registered bulk manufacturers of
 the affected basic class(es), and
 applicants therefore, may submit
 electronic comments on or objections to
 the issuance of the proposed registration
 on or before May 4, 2023. Such persons
 may also file a written request for a
 hearing on the application on or before
 May 4, 2023.

ADDRESSES: The Drug Enforcement
 Administration requires that all
 comments be submitted electronically
 through the Federal eRulemaking Portal,
 which provides the ability to type short
 comments directly into the comment
 field on the web page or attach a file for
 lengthier comments. Please go to
<https://www.regulations.gov> and follow
 the online instructions at that site for
 submitting comments. Upon submission
 of your comment, you will receive a
 Comment Tracking Number. Please be
 aware that submitted comments are not
 instantaneously available for public
 view on <https://www.regulations.gov>. If
 you have received a Comment Tracking
 Number, your comment has been
 successfully submitted and there is no
 need to resubmit the same comment. All
 requests for a hearing must be sent to:
 (1) Drug Enforcement Administration,
 Attn: Hearing Clerk/OALJ, 8701
 Morrisette Drive, Springfield, Virginia
 22152; and (2) Drug Enforcement
 Administration, Attn: DEA Federal
 Register Representative/DPW, 8701
 Morrisette Drive, Springfield, Virginia
 22152. All requests for a hearing should
 also be sent to: Drug Enforcement
 Administration, Attn: Administrator,

8701 Morrisette Drive, Springfield,
 Virginia 22152.

SUPPLEMENTARY INFORMATION: In
 accordance with 21 CFR 1301.34(a), this
 is notice that on February 8, 2023, Sharp
 Clinical Services, LLC, 2400 Baglyos
 Circle, Bethlehem, Pennsylvania 18020-
 8024, applied to be registered as an
 importer of the following basic class(es)
 of controlled substance(s):

Controlled substance	Drug code	Schedule
Gamma Hydroxybutyric Acid	2010	I
3,4-Methylenedioxymethamphetamine.	7405	I
5-Methoxy-N-N-dimethyltryptamine.	7431	I

The company plans to import the
 listed controlled substances for
 distribution and clinical trials. No other
 activities for these drug codes are
 authorized for this registration.

Approval of permit applications will
 occur only when the registrant's
 business activity is consistent with what
 is authorized under 21 U.S.C. 952(a)(2).
 Authorization will not extend to the
 import of Food and Drug
 Administration-approved or non-
 approved finished dosage forms for
 commercial sale.

Matthew Strait,
Deputy Assistant Administrator.
 [FR Doc. 2023-06948 Filed 4-3-23; 8:45 am]
BILLING CODE 4410-09-P

comments be submitted electronically
 through the Federal eRulemaking Portal,
 which provides the ability to type short
 comments directly into the comment
 field on the web page or attach a file for
 lengthier comments. Please go to
<https://www.regulations.gov> and follow
 the online instructions at that site for
 submitting comments. Upon submission
 of your comment, you will receive a
 Comment Tracking Number. Please be
 aware that submitted comments are not
 instantaneously available for public
 view on <https://www.regulations.gov>. If
 you have received a Comment Tracking
 Number, your comment has been
 successfully submitted and there is no
 need to resubmit the same comment. All
 requests for a hearing must be sent to:
 (1) Drug Enforcement Administration,
 Attn: Hearing Clerk/OALJ, 8701
 Morrisette Drive, Springfield, Virginia
 22152; and (2) Drug Enforcement
 Administration, Attn: DEA Federal
 Register Representative/DPW, 8701
 Morrisette Drive, Springfield, Virginia
 22152. All requests for a hearing should
 also be sent to: Drug Enforcement
 Administration, Attn: Administrator,
 8701 Morrisette Drive, Springfield,
 Virginia 22152.

SUPPLEMENTARY INFORMATION: In
 accordance with 21 CFR 1301.34(a), this
 is notice that on January 28, 2023,
 SpecGX LLC, 3600 North 2nd Street,
 Saint Louis, Missouri 63147, applied to
 be registered as an importer of the
 following basic class(es) of controlled
 substance(s):

Controlled substance	Drug code	Schedule
Marihuana	7360	I
Phenylacetone	8501	II
Coca Leaves	9040	II
Thebaine	9333	II
Opium, Raw	9600	II
Poppy Straw Con- centrate.	9670	II
Tapentadol	9780	II

The company plans to import the
 listed controlled substances for bulk
 manufacture into Active Pharmaceutical
 Ingredients (API) for distribution to its
 customers. In reference to Tapentadol
 (9780) and Thebaine (9333), the
 company plans to import intermediate
 forms of these controlled substances for
 further manufacturing prior to
 distribution to its customers. In
 reference to drug code 7360
 (Marihuana), the company plans to
 import synthetic cannabinol. No other
 activity for this drug is authorized for
 this registration. Placement of these
 codes onto the company's registration
 does not translate into automatic
 approval of subsequent permit

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-1177]

**Importer of Controlled Substances
 Application: SpecGX LLC**

AGENCY: Drug Enforcement
 Administration, Justice.

ACTION: Notice of application.

SUMMARY: SpecGX, LLC has applied to
 be registered as an importer of basic
 class(es) of controlled substance(s).
 Refer to Supplemental Information
 listed below for further drug
 information.

DATES: Registered bulk manufacturers of
 the affected basic class(es), and
 applicants therefore, may submit
 electronic comments on or objections to
 the issuance of the proposed registration
 on or before May 4, 2023. Such persons
 may also file a written request for a
 hearing on the application on or before
 May 4, 2023.

ADDRESSES: The Drug Enforcement
 Administration (DEA) requires that all